Inflammatory muscle disease affecting two or more anatomically distinct sites, classified as 'other' myositis when it does not fall under infective, foreign body, or calcifying subtypes.
Verified May 8, 2026 · 5 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 12
- Region
- Multi-region
Documentation tips
What should appear in the chart to support M60.89.
Source · Editorial brief grounded in 5 cited references ↓
- Name every affected muscle group or anatomical region explicitly — 'bilateral shoulder and hip girdle weakness with MRI-confirmed inflammation' anchors the 'multiple sites' requirement.
- Record creatine kinase (CK/CPK) value and trend; elevated muscle enzymes are objective support for inflammatory myopathy and strengthen medical necessity.
- Document autoantibody panel results (e.g., anti-Jo-1, anti-SRP, anti-Mi-2) when obtained — positive results support specificity and may drive rheumatology co-management coding.
- State the exclusion of inclusion body myositis in the assessment if IBM was on the differential; this satisfies the Excludes2 note at M60 and protects against audit.
- If MRI or ultrasound was performed, document specific findings (edema, signal change, involved muscle names) rather than just 'abnormal imaging' — this substantiates multi-site involvement.
- Record duration and treatment history; myositis persisting beyond a few weeks and failing standard analgesic therapy strengthens the chronic inflammatory diagnosis and justifies specialist referral coding.
Related CPT procedures
Procedure codes commonly billed with M60.89. Linking the right diagnosis to the right procedure is what establishes medical necessity.
Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis
Common coding pitfalls
The recurring mistakes coders make with M60.89 and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Coding M60.89 when inclusion body myositis (G72.41) is documented — IBM carries an Excludes2 note at M60, meaning it requires its own separate code and should not be lumped into M60.89.
- Defaulting to M60.9 (unspecified myositis) when the record documents multiple sites — M60.89 is the specific billable code and should always be preferred over M60.9 when multi-site involvement is documented.
- Using M60.89 for dermatomyositis or polymyositis with a defined connective tissue disease — those conditions map to M33.x (dermatomyositis) or may require a primary systemic disease code with M60.89 as a secondary descriptor only.
- Assigning M60.88 (other site) instead of M60.89 when two or more distinct sites are involved — M60.88 is for a single 'other' anatomical site not listed, not for multi-regional disease.
- Failing to code the underlying cause when myositis is due to a drug or systemic condition — use an additional code for adverse effect (T36–T50 with 5th/6th character 5) or the primary condition when etiology is established.
Clinical context
Source · Editorial summary grounded in 5 cited references ↓
M60.89 is the correct code when documented myositis spans multiple body regions and does not meet criteria for a more specific subtype — such as infective myositis (M60.0x), foreign body granuloma in muscle (M60.2x), or calcification/ossification syndromes (M61.x). Typical clinical presentations include proximal muscle weakness at bilateral shoulders and hips, elevated creatine kinase, and MRI findings of edema in multiple muscle groups. Autoimmune-driven polymyositis patterns without a separately classifiable connective tissue disease diagnosis commonly land here.
Before assigning M60.89, rule out inclusion body myositis (IBM), which is explicitly excluded from the M60 category via an Excludes2 note pointing to G72.41. IBM can coexist and be coded separately, but the inflammatory pattern must be documented as distinct from IBM. Also confirm that the underlying condition is not more precisely captured by a systemic autoimmune code (e.g., dermatomyositis under M33.x) — those carry their own specificity hierarchy.
Within the M60.8x family, M60.89 (multiple sites) is the only code that captures bilateral or multi-regional involvement in a single code. If documentation names only one region, use the site-specific codes (M60.811–M60.879). Use M60.80 only when the site is genuinely unspecified. M60.9 (myositis, unspecified) should be a last resort — it signals absent clinical specificity and can trigger payer edits.
Sibling codes
Other billable codes under M60.8 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 5 cited references ↓
01When should I use M60.89 versus M60.9?
02Does M60.89 cover polymyositis?
03Inclusion body myositis affects multiple muscles — can I use M60.89 for it?
04What CPT procedures are commonly paired with M60.89?
05Is M60.89 valid for drug-induced myositis at multiple sites?
06How does M60.89 differ from M60.88?
07Can M60.89 be a primary diagnosis on a claim?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026 (effective October 1, 2025)
- 02icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M60-M63/M60-/M60.89
- 03aapc.comhttps://www.aapc.com/codes/icd-10-codes/M60.89
- 04ecgwaves.comhttps://ecgwaves.com/icd-code/m60-89-other-myositis-multiple-sites-icd-10-code-in-m60-m79-soft-tissue-disorders/
- 05mdclarity.comhttps://www.mdclarity.com/icd-codes/m60-89
Mira AI Scribe
Mira AI Scribe captures the specific muscle groups affected (e.g., bilateral deltoids, hip flexors), objective findings (CK elevation, MRI edema in named muscles), autoantibody results, and duration of symptoms across sites — the data points that validate 'multiple sites' and prevent a downcode to M60.9 or an unspecified-site code that triggers payer scrutiny.
See how Mira captures M60.89 documentation